Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

IJMS, Free Full-Text

Figure 1 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Cancers, Free Full-Text

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study - Advances in Radiation Oncology